New York City, NY -- (SBWIRE) -- 01/09/2014 -- To receive alerts before the crowd, please take 7 seconds to sign up for our Premium SMS Alerts. Grab your cell phone and text the word "PICKS" to "555888”.
StockMarketIntel.com issues a special report on the following stocks: NuPathe Inc (NASDAQ:PATH), Zalicus Inc (NASDAQ:ZLCS), Arca Biopharma Inc (NASDAQ:ABIO), Athersys, Inc. (NASDAQ:ATHC)
NuPathe Inc (NASDAQ:PATH) gained 35.60%, trading on 7.35 million shares, to end the trade at $4.38. The stock changed hands in a range of $4.34 to $4.49, bringing its market capitalization to about $137.22 million. If we look at its trading history of the past 52 weeks, the share price suffered a low of $1.57 and was moved to the maximum level of $4.49. NuPathe, Inc. develops therapeutics for diseases of the central nervous system including neurological and psychiatric disorders. The Companys products are NP201 for the continuous symptomatic treatment of Parkinson's disease and NP202 for the long-term treatment of schizophrenia and bipolar disorder. The Company completed a pivotal Phase III clinical trial for Zelrix, an active, single-use transdermal sumatriptan patch for the treatment of acute migraine.
What was the Moving Force behind PATH on Bullish Run? Read This Research Report
Zalicus Inc (NASDAQ:ZLCS) added 34.85%, to complete the trading session at $1.78, with a total volume of 11.99 million shares. The stock, on average, trades on a volume of 1.46 million shares. It floated in a range of $1.32 to $2.00 during the last trading session, with a beta value of 1.69. Its market capitalization now moved to about $46.44 million. In the past 52 weeks, the share price has not declined below $0.88 and above $8.28. Zalicus Inc. (Zalicus) is a biopharmaceutical company that discovers and developsl treatments for patients suffering from pain and immuno-inflammatory diseases. The Company has a portfolio of clinical-stage product candidates targeting pain and immuno-inflammatory diseases and have entered into multiple revenue-generating collaborations with large pharmaceutical companies relating to other products, product candidates and drug discovery technologies.
For How Long ZLCS will fight for Profitability? Read This Trend Analysis report
Arca Biopharma Inc (NASDAQ:ABIO) recorded a fall of 25.56% and was in a range of $2.15-$2.54 before closing at $2.26. The stock completed the day with a total volume of 16.27 million shares, versus an average volume of 1.65 million shares. The share price hit its 52-week low of $1.13 and $5.93 was the best price. ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company's principal focus is developing genetically-targeted therapies for heart failure and other cardiovascular diseases. ARCA's lead product candidate is Gencaro TM (bucindolol hydrochloride), a pharmacologically beta-blocker and mild vasodilator being developed for the treatment of chronic heart failure (HF).
Will ABIO Bounce Back After yesterday’s Sharp Sell off? Find Out Here
Athersys, Inc. (NASDAQ:ATHC) added 24.05% yesterday, bringing its market capitalization around $276.45 million. The share price, after opening at $3.20, made a high of $3.97 and hovered above $3.18 to end the day at $3.92. The total number of shares that changed hands during the session was 7.08 million shares, as compared to average trading volume of 1.65 million shares. Athersys Inc. is a biopharmaceutical company engaged in the field of regenerative medicine. During the year ended December 31, 2011 the Company is developing its platform product, MultiStem, a allogeneic stem cell product that has been evaluated in two completed Phase I clinical trials and as of December 31, 2011, is being evaluated in two ongoing Phase II clinical trials.
For How Long ATHX Gloss will Attract Investors? Find out via this report
To receive alerts before the crowd, please take 7 seconds to sign up for our Premium SMS Alerts. Grab your cell phone and text the word "PICKS" to "555888”.
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list.
Neither StockMarketIntel.com, nor its employees and affiliates are registered as investment advisors or broker/dealers in any jurisdiction whatsoever. Through use of this website viewing or using you agree to hold StockMarketIntel.com, its operators, owners, employees, and affiliates harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Readers should always do their own due diligence and consult a financial professional. StockMarketIntel.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and StockMarketIntel.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled company. Any opinions expressed on this website are statements of judgment as of the date of publication and are subject to change without further notice, and may not necessarily be reprinted in future publications or elsewhere.
Read Full disclaimer at: http://stockmarketintel.com/Disclaimer.htm
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)